Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Obesity

In brief

The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults

Key facts

Study ID

NCT00396448

Run by

Pfizer

People needed

1253

Starts

2007-02-01

Expected to finish

2009-02-01

Last updated by the study team

2012-11-07

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Obese adults with a body mass index > or = 30 kg/m ; > or = 27 kg/m2 for those with obesity-related comorbidities including hypertension and dyslipidemia

You may not qualify if…

• Pregnancy
• Diabetes
• Adults with serious or unstable current or past medical conditions

Where it is running

• Pfizer Investigational Site — Newport Beach, California, United States
• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Springfield, Illinois, United States
• Pfizer Investigational Site — Overland Park, Kansas, United States
• Pfizer Investigational Site — Louisville, Kentucky, United States
• Pfizer Investigational Site — Farmington Hills, Michigan, United States
• Pfizer Investigational Site — Cary, North Carolina, United States
• Pfizer Investigational Site — Raleigh, North Carolina, United States
• Pfizer Investigational Site — Wilmington, North Carolina, United States
• Pfizer Investigational Site — Winston-Salem, North Carolina, United States
• Pfizer Investigational Site — Portland, Oregon, United States
• Pfizer Investigational Site — Anderson, South Carolina, United States
• Pfizer Investigational Site — Johnson City, Tennessee, United States
• Pfizer Investigational Site — Bountiful, Utah, United States
• Pfizer Investigational Site — Capital Federal, Buenos Aires, Argentina
• Pfizer Investigational Site — Ramos Mejía, Buenos Aires, Argentina
• Pfizer Investigational Site — Córdoba, Córdoba Province, Argentina
• Pfizer Investigational Site — Villa Carlos Paz, Córdoba Province, Argentina
• Pfizer Investigational Site — Buenos Aires, Argentina
• Pfizer Investigational Site — Capital Federal, Argentina
• Pfizer Investigational Site — Caringbah, New South Wales, Australia
• Pfizer Investigational Site — Miranda, New South Wales, Australia
• Pfizer Investigational Site — Wollongong, New South Wales, Australia
• Pfizer Investigational Site — Caboolture, Queensland, Australia
• Pfizer Investigational Site — Peoria, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.